Keros Therapeutics, Inc.

Keros Therapeutics, Inc.

KROSNYSE / NASDAQHealthcareSmall cap

$11.08-$0.31 (-2.7%)

Last close · Data as of Nov 20, 2026

Market cap
$213.2M
P/E
2.4x
EV / EBITDA
-0.8x
Revenue
$244.1M
Net margin
35.7%
ROCE
21.3%

-34.1% over the last year

Keros Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.8%
3M
+1.2%
6M
+0.9%
1Y
-34.1%
5Y
Hidden
  • This period includes a one-day price step on 12 Dec 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.31 (-2.7%) from $11 to $11 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in KROS, bought on each weekday since 2021.

News & filings

What Keros Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthReturn on equity rose from -32.8% to 28.7% between fiscal 2024 and fiscal 2025.

Concerns (1)

  • The price fell as much as 58% from a high within the last year.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.

Read moreShow less

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Sector
Healthcare
Shares outstanding
37.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$213.2M
P/E
2.4x
P/B
0.7x
EV / EBITDA
-0.8x
EV / Sales
-0.2x
P/S
0.9x
52-week high
$21.84
52-week low
$9.17

Profitability

Operating margin
27.7%
Net margin
35.7%
EBITDA margin
28.3%
ROE
28.7%
ROCE
21.3%
ROIC
196.3%
ROA
25.7%
Asset turnover
0.72

Growth

Revenue
$244.1M
Revenue growth, 1Y
6775.0%
Net profit growth, 1Y
-146.4%
Free cash flow
$106.0M

Solvency

Current ratio
15.45
Debt / Equity
0.06
Debt / Assets
0.05
CFO / Net profit
1.24
Cash / Market cap
134.8%

Where the revenue went

Of every $100 of FY2025 revenue, $36 was left as net income.

Keros Therapeutics, Inc. income statement flow, FY2025
Keros Therapeutics, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueGross profit$244.1M
Gross profitResearch and development$129.6M
Gross profitSelling, general and administrative$46.9M
Gross profitOther operating expenses$0.00
Gross profitOperating income$67.6M
Operating incomePretax income$67.6M
Interest and other incomePretax income$24.3M
Pretax incomeTax and other$4.9M
Pretax incomeNet income$87.0M

Revenue and net profit

Revenue grew 6775.0% in FY2025; net profit is the dashed line.

Keros Therapeutics, Inc. revenue and net profit by fiscal year
Keros Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$104.7M
FY2023$151.0k-$153.0M
FY2024$3.5M-$187.4M
FY2025$244.1M$87.0M

Cash flows

FY2025: $107.5M from operations, $106.0M free after investment (dashed).

Keros Therapeutics, Inc. operating and free cash flow by fiscal year
Keros Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$70.1M-$71.3M
FY2023-$124.5M-$127.0M
FY2024-$160.9M-$162.8M
FY2025$107.5M$106.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$244.1M+6,775.0%1Y
EBITDA
$69.1M
Net profit
$87.0M
Cash from operations
$107.5M
Free cash flow
$106.0M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$244.1M$69.1M$87.0M$106.0M28.7%+6775.0%-146.4%

Monthly returns

Month-by-month returns of KROS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$338.0M
Liabilities$34.9M
Equity$303.1M
Paid-in capital$1.2B
Retained earnings-$481.8M
Treasury stock$384.6M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; KROS highlighted.

P/E against peers

KROS trades at 2.4x earnings against a peer median of -2.3x.

  1. Keros Therapeutics, Inc. (this company)2.4x

Not shown (no positive earnings and no EV / Sales): Inhibikase Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Keros Therapeutics, Inc.KROSthis company$213.2M2.4x0.7x28.7%-0.8x
Foghorn Therapeutics Inc.FHTX$219.6M-3.0x-2.0x68.5%-2.3x
Inhibikase Therapeutics, Inc.IKT$219.2M-4.5x1.3x-27.9%-1.5x
Voyager Therapeutics, Inc.VYGR$218.7M-1.8x1.1x-61.1%-1.5x
Utah Medical Products, Inc.UTMD$216.5M19.2x1.8x9.5%9.1x
Pro-Dex, Inc.PDEX$213.9M23.8x5.8x24.5%16.3x
RxSight, Inc.RXST$211.1M-5.4x0.8x-14.1%-5.7x
Atrium Therapeutics, Inc.RNA$210.4M-2.7x1.0x-37.0%0.7x
Accendra Health, Inc.ACH$202.9M-0.2x-0.4x238.8%9.3x
Peer median—-2.3x1.1x-2.3%-0.4x

Year-to-date ROI

KROS since 1 January, against earlier years.

Historical volatility

KROS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Keros Therapeutics, Inc. operating margin by fiscal year
Keros Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2023-111693.3%
FY2024-5904.2%
FY202527.7%
LineFY2025
Operating expensesOperating Expense$176.5M
Research and developmentResearch And Development$129.6M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$176.5M
Pretax incomePretax Income$91.9M

Learn while you research

Academy chapters picked for Keros Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 2.4 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Growth Investing6775% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  5. 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  6. 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
Browse the full Equiscale Academy →